ATE493437T1 - Polypeptide für die oligomerisierung von antigenen - Google Patents

Polypeptide für die oligomerisierung von antigenen

Info

Publication number
ATE493437T1
ATE493437T1 AT05770330T AT05770330T ATE493437T1 AT E493437 T1 ATE493437 T1 AT E493437T1 AT 05770330 T AT05770330 T AT 05770330T AT 05770330 T AT05770330 T AT 05770330T AT E493437 T1 ATE493437 T1 AT E493437T1
Authority
AT
Austria
Prior art keywords
polypeptides
polypeptide
oligomerisation
oligomerization
antigens
Prior art date
Application number
AT05770330T
Other languages
English (en)
Inventor
Barbara Capecchi
Vega Masignani
Rino Rappuoli
Maria Scarselli
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE493437T1 publication Critical patent/ATE493437T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT05770330T 2004-07-23 2005-07-22 Polypeptide für die oligomerisierung von antigenen ATE493437T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59064804P 2004-07-23 2004-07-23
PCT/IB2005/002528 WO2006011060A2 (en) 2004-07-23 2005-07-22 Polypeptides for oligomeric assembly of antigens

Publications (1)

Publication Number Publication Date
ATE493437T1 true ATE493437T1 (de) 2011-01-15

Family

ID=35447945

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05770330T ATE493437T1 (de) 2004-07-23 2005-07-22 Polypeptide für die oligomerisierung von antigenen

Country Status (8)

Country Link
US (1) US7915218B2 (de)
EP (1) EP1778725B1 (de)
CN (1) CN101014618B (de)
AT (1) ATE493437T1 (de)
CA (1) CA2574375C (de)
DE (1) DE602005025647D1 (de)
ES (1) ES2355980T3 (de)
WO (1) WO2006011060A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
NZ556651A (en) 2005-01-21 2010-05-28 Epitopix Llc Yersinia spp. polypeptides and methods of use
AU2006279323B2 (en) * 2005-08-16 2013-08-01 Merck Sharp & Dohme Corp. Influenza recombinant subunit vaccine
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP1972350A1 (de) * 2007-03-20 2008-09-24 Rijksuniversiteit Groningen Duales Targeting-System
EA200700940A1 (ru) * 2007-04-27 2007-12-28 Петр Генриевич ЛОХОВ Способ получения противоопухолевой вакцины на основе поверхностных антигенов эндотелиальных клеток
EP2003144A1 (de) * 2007-06-15 2008-12-17 Institut Pasteur Diagnose- oder Screening-Verfahren für eine Arbovirusinfektion, Reagenzien für dieses Verfahren und deren Anwendung
GB0711858D0 (en) * 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
WO2009049013A2 (en) * 2007-10-09 2009-04-16 Tufts University Cholera vaccines
US8399240B2 (en) * 2008-02-22 2013-03-19 National University Corporation Nagoya University Method and gene for providing or enhancing nonspecific adhesive property and/or autoagglutinating property for microorganisms
CA2768186A1 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
CN107913396B (zh) 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
CA2835644C (en) 2011-05-13 2021-06-15 Novartis Ag Pre-fusion rsv f antigens
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
WO2013150142A1 (en) * 2012-04-05 2013-10-10 Ludwig-Maximilians-Universität München Method for the preparation of a strain- adapted vaccine
BR112015001390B1 (pt) 2012-07-26 2024-04-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc Proteína de fusão, ácido nucleico isolado e uso de uma composição de vacina
WO2014016152A1 (en) 2012-07-27 2014-01-30 Institut National De La Sante Et De La Recherche Medicale Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2021188818A1 (en) * 2020-03-19 2021-09-23 The United States Of America As Represented By The Secretary Of The Navy Vaccine constructs and compositions and methods of use thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
WO2021249013A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Vaccine compositions, methods, and uses thereof
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9106048D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
US5837544A (en) * 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
US6716429B1 (en) 1997-10-01 2004-04-06 Dana-Farber Cancer Institute, Inc. Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp 41 glycoprotein ectodomain
CA2410525A1 (en) 2000-05-26 2001-11-29 Mochida Pharmaceuticals Co., Ltd. Fas ligand-fused proteins

Also Published As

Publication number Publication date
CN101014618B (zh) 2013-01-02
EP1778725B1 (de) 2010-12-29
US20080260769A1 (en) 2008-10-23
WO2006011060A2 (en) 2006-02-02
DE602005025647D1 (de) 2011-02-10
US7915218B2 (en) 2011-03-29
WO2006011060A3 (en) 2006-04-06
CA2574375A1 (en) 2006-02-02
ES2355980T3 (es) 2011-04-01
CN101014618A (zh) 2007-08-08
CA2574375C (en) 2015-03-17
EP1778725A2 (de) 2007-05-02

Similar Documents

Publication Publication Date Title
ATE493437T1 (de) Polypeptide für die oligomerisierung von antigenen
MX2014005546A (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
DE60232577D1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
MX2021013355A (es) Composiciones de proteínas de fusión quiméricas modificadas y métodos de uso de las mismas.
PH12019500782A1 (en) Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
CY1120849T1 (el) Αντισωμα που συνδεεται σε ανθρωπινο cd3
CU20180084A7 (es) Inmunoglobulina con fabs en tándem
MX2018006583A (es) Anticuerpos y fragmentos de anticuerpo para la conjugacion sitio-especifica.
PE20150023A1 (es) Proteinas de union a antigeno st2
WO2011100566A3 (en) Methods for identifying and isolating cells expressing a polypeptide
UY33983A (es) Proteínas de Unión de Tipo Anticuerpo con Región Variable Dual que Tienen Orientación de la Región de Unión con Entrecruzamiento.
UY37206A (es) Proteínas de unión triespecíficas y/o trivalentes
NZ591704A (en) Peptide vaccines for cancers expressing tumor-associated antigens
WO2013155526A3 (en) Sortase- modified vhh domains and uses thereof
PH12021550885A1 (en) Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
SG10201806693XA (en) Anti-myostatin antibodies and methods of use
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
ATE387629T1 (de) Gemeinsame epitope von antigenen aus einer multigen-familie
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
MX2021000263A (es) Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma.
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
AR085167A1 (es) Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit
MX2019002178A (es) Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties